Research Demonstrates Ability of the MYO-VAD(TM) to Help Prevent Progression of Heart Disease; Paper Presented by Mark A. Anstadt, M.D. Describes Animal Studies.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB:BIPH; FWB:BTN), a developer of next-generation medical technology, announced today the results of recent animal studies that demonstrated the potential of the MYO-VAD(TM) cardiac recovery system to help prevent the progression of heart failure when used to support a diseased or failing heart.

The finding was featured in a paper presented at a recent ASAIO (American Society for Artificial Internal Organs) conference by Mark A. Anstadt, M.D., FACS, Associate Professor of Cardiothoracic Surgery at Wright State University, and colleagues. Dr. Anstadt is chairman of the scientific advisory board for MYOTECH, LLC, the company developing the MYO-VAD. Biophan Technologies, Inc. holds a 42% interest in MYOTECH, with rights to acquire a majority position, and is leading MYOTECH's business development activities.

"Minimizing additional damage to the myocardium following a heart attack is important to prevent the further progression of the disease," said Jeffrey Helfer, President of Biophan's Cardiovascular division. "A previous version of the MYO-VAD technology has already saved lives in emergency-use situations. The ability of this technology to provide acute support has been shown, and this data is further evidence of the potential of the MYO-VAD technology to successfully compete in the rapidly emerging market for therapeutic treatment of heart disease."

The MYO-VAD is the first in a family of products based on Direct Mechanical Ventricular Actuation (DMVA) technology. It consists of a flexible polymer cup that fits around the heart, coupled to a drive unit, which pumps the heart to restore blood flow. Because it does not come into direct contact with circulating blood, the MYO-VAD promises to provide substantial advantages over today's cardiac assist devices by eliminating serious and potentially fatal problems, including clotting and stroke, bleeding, and infection.

Due to its technically simple insertion and removal requirements, anticipated lower rates of complication, and lower device cost, the MYO-VAD is expected to provide a significant reduction in the cost of treating heart failure patients. This promises to extend the physician's ability to treat heart failure and help save thousands of lives. The simple nature of the MYO-VAD also promises to extend the use of the device to most hospitals, not just the small number of specialized transplant or cardiac care facilities required by most existing cardiac assist devices.

For more information on the MYO-VAD please visit this link: www.biophan.com/index.php?option=com_content&task=view&id=18&Itemid=40

About Biophan Technologies:

Biophan develops and markets cutting-edge technologies for the medical device industry that provide competitive advantages. The Company's founding goal was to make all biomedical devices capable of safely and successfully working with magnetic resonance imaging (MRI). Having solved these problems, the Company has begun to license its technologies for MRI safety and image compatibility to leading device manufacturers. Biophan's technologies enable medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and implants such as stents to be safely and/or effectively imaged under MRI. The Company is helping to commercialize the MYOTECH MYO-VAD(TM), a new, MRI-compatible cardiac recovery system which has significant potential to improve the treatment of many forms of acute and chronic heart disease. Other applications in development include drug delivery and power systems which derive energy from body heat. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of over 200 U.S. and foreign patents, licenses, or applications. This total includes 56 issued U.S. patents, and over 100 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials, and photonics. Biophan has joint development and licensing agreements with Boston Scientific Corporation and NASA's Ames Center for Nanotechnology. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN. For more information on Biophan please visit our website at www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.